NCT01716897

An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

A Randomized, Open-label, 3-treatment Crossover Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption in Healthy Caucasian Male Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: Male
• Age: 30 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will be a single-center, open-label, randomized, 3-treatment crossover study of single oral doses of an API-capsule formulation of E2609 under fasted conditions and a tablet formulation administered under fed and fasted conditions in healthy subjects.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	E2609

Timeline

• Start date: 2012-10-01
• Primary completion: 2012-12-01
• Completion: 2013-02-01
• First posted: 2012-10-30
• Last updated: 2013-05-22

Locations

1 site across 1 country: United States